Are germ cell tumors part of the Li-Fraumeni cancer family syndrome?
Affiliation
Department of Epidemiology and Social Oncology, Christie Hospital, Manchester, England.Issue Date
1989-10-15
Metadata
Show full item recordAbstract
The occurrence of six cases of germ cell tumors, five testicular and one ovarian, in relatives of children with bone or soft tissue sarcomas is described. It is proposed that germ cell tumors may be an uncommon manifestation of the genetic predisposition to cancer that exists in the Li-Fraumeni cancer family syndrome.Citation
Are germ cell tumors part of the Li-Fraumeni cancer family syndrome? 1989, 42 (2):221-6 Cancer Genet CytogenetJournal
Cancer Genetics and CytogeneticsDOI
10.1016/0165-4608(89)90090-3PubMed ID
2790757Type
ArticleLanguage
enISSN
0165-4608EISSN
1873-4456ae974a485f413a2113503eed53cd6c53
10.1016/0165-4608(89)90090-3
Scopus Count
Collections
Related articles
- The Li-Fraumeni cancer family syndrome.
- Authors: Birch JM
- Issue date: 1990 May
- Dysgerminoma, gonadoblastoma, and testicular germ cell neoplasia in phenotypically female and male siblings with 46 XY genotype.
- Authors: Kingsbury AC, Frost F, Cookson WO
- Issue date: 1987 Jan 15
- Occurrence of seminoma and dysgerminoma in father and daughter.
- Authors: Yule SM, Dawes PJ, Malcolm AJ, Pearson AD
- Issue date: 1994 Mar-Apr
- Patterns of cancer in the families of children with soft tissue sarcoma.
- Authors: Hartley AL, Birch JM, Blair V, Kelsey AM, Harris M, Jones PH
- Issue date: 1993 Aug 1
- Cancer in relatives of survivors of childhood sarcoma.
- Authors: Burke E, Li FP, Janov AJ, Batter S, Grier H, Goorin A
- Issue date: 1991 Mar 1
Related items
Showing items related by title, author, creator and subject.
-
Treatment for non small cell lung cancer, small cell lung cancer and pleural mesothelioma within the EORTC Lung Cancer Group: past, present and future.O'Brien, M; van Meerbeeck, J; Surmont, V; Faivre-Finn, Corinne (2012)
-
Ovarian cancer among 8,005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2.Ingham, S; Warwick, J; Buchan, I; Sahin, S; O'Hara, Catherine; Moran, Anthony; Howell, Anthony; Evans, D; Centre for Health Informatics, Institute of Population Health, The University of Manchester, Manchester, UK. (2013-06)Mutations in BRCA1/2 genes confer ovarian, alongside breast, cancer risk. We examined the risk of developing ovarian cancer in BRCA1/2-positive families and if this risk is extended to BRCA negative families.
-
AZD8186 study 1: phase I study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of AZD8186 in patients with advanced castration-resistant prostate cancer (CRPC), squamous non-small cell lung cancer, triple negative breast cancer and with PTEN-deficient/mutated or PIK3CB mutated/amplified malignancies, as monotherapy and in combination with vistusertib (AZD2014) or abiraterone acetate.Lillian, S; De Bono, J; Higano, C; Shapiro, G; Brugger, W; Mitchell, P; Colebrook, S; Klinowska, T; Barry, S; Dean, Emma J; et al. (2016-12)